AfshinSalsaliMD

Diabetes, Lipid Metabolism

Physician

Dr. Salsali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
125 Paterson St
Ste 5200
New Brunswick, NJ 08901
Phone+1 732-235-7219

University of Vermont Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2001 - 2003
Quinnipiac University Frank H. Netter MD School of Medicine/St Vincent's Medical CenterResidency, Internal Medicine, 1998 - 2001
Tehran University of Medical Sciences School of MedicineClass of 1991

PubMed

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbAlevels (STEP-HFpEF DM): a prespecified analysis of...
Melanie J Davies, Peter van der Meer, Subodh Verma, Shachi Patel, Khaja M Chinnakondepalli
The Lancet. Diabetes & Endocrinology. 2025-01-20
91 citations
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
Jan Biegus, Adriaan A Voors, Sean P Collins, Mikhail N Kosiborod, John R Teerlink
European Heart Journal. 2023-01-01
25 citations
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Adriaan A Voors, Kevin Damman, John R Teerlink, Christiane E Angermann, Sean P Collins
European Journal of Heart Failure. 2022-10-01

Journal Articles

Empagliflozin Compared with Glimepiride in Metformin‐Treated Patients with Type 2 Diabetes: 208‐Week Data from a Masked Randomized Controlled Trial
Afshin Salsali, MD, Diabetes, Obesity and Metabolism

Empagliflozin Lowers High Blood Pressure, Blood Sugar in DiabeticsJune 23rd, 2014